Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) (MASH)
A Study to Assess the Effect of Vonafexor on Kidney Function in Subjects With Impaired Renal Function and Suspected MASH
Sponsor: Enyo Pharma
Terminated
Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.
Other terminated trials from Enyo Pharma
This observational or N/A phase trial investigates Chronic Kidney Disease Stage 2 and Chronic Kidney Disease Stage 3 and is currently terminated or withdrawn. Enyo Pharma leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Study Description(click to expand)This is a phase 2, open-label, two-dose, randomized, parallel arms, single center study where subjects are participating for up to 32 weeks:
* Screening: 4 weeks
* Treatment: 16 weeks
* Follow-up: 12 weeks
This is a phase 2, open-label, two-dose, randomized, parallel arms, single center study where subjects are participating for up to 32 weeks:
* Screening: 4 weeks * Treatment: 16 weeks * Follow-up: 12 weeks
Status Flow
Change History
3 versions recorded-
Apr 28, 2026 — Present [daily]
Terminated
Status: Recruiting → Terminated · Phase: PHASE2 → None
-
Aug 2025 — Apr 2026 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected MASH. In addition, the non-invasive multiparametric magnetic resonance imaging assessment of functional and structural changes in the kidney and in the liver will be investigated.
Contact Information
- Enyo Pharma
For direct contact, visit the study record on ClinicalTrials.gov .